Suven Life Sciences – the Drug Firm on 31 December 2012 won patents on three products for CNS molecules. Among the patents two are from Eurasia with patent numbers 016594 and 017007 and one is from Canada with patent number 2683124. These are the New Chemical Entities (NCEs) and would be used for the treatment of disorders related to Neurodegenerative diseases. The validity of these patents would last up to 2027.

Selective 5-HT compounds discovered by the Suven are also part of the patents on which the claims have been granted and these HT compounds are developed as the therapeutic agents, which can be used for the treatment of impairment cognitive that are associated with the Neurodegerative disorders such as Attention Deficient Hyperactivity Disorder (ADHD), Alzheimer disease, Parkinson, Huntington’s disease and Schizophrenia.

After winning these patents, the list of patents in the bag of Suven from Canada and Eurasia rose up to 10 and 10 respectively and each of these patents are the pat of exclusive Intellectual Property of Suven that were achieved following the internal discovery research efforts.